OCULAR THERAPEUTIX,INC. (NASDAQ:OCUL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
W. Bradford Smith notified Ocular Therapeutix, Inc. (the “Company”) on March 20, 2017 of his resignation from his position as Chief Financial Officer of the Company, effective March 31, 2017, to pursue other opportunities. Mr. Smith has agreed to provide consulting services on an as needed hourly basis to the Company through May 31, 2017 to assist with the transition to a successor.
In connection with the departure of Mr. Smith, James Fortune, the Company’s Chief Operating Officer, will assume the roles of principal financial officer and principal accounting officer on an interim basis, effective April 1, 2017. Mr. Fortune, age 58, has served as the Company’s Chief Operating Officer since 2008. Mr. Fortune also served as the Chief Operating Officer of Augmenix, Inc. from 2008 to April 2014 and of AccessClosure, Inc. from 2008 to 2010. Prior to joining the Company, Mr. Fortune served as the Chief Operating Officer of Confluent Surgical, Inc. Previously, he held various senior management roles with the orthopedic and neurosurgical divisions of Johnson & Johnson. Mr. Fortune holds a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute.
Mr. Fortune has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Fortune and any other person to which he is being appointed as the principal financial officer and principal accounting officer of the Company.